Switching elderly chronic psychotic patients to olanzapine

Yoram Barak*, Eyal Shamir, Ilona Mirecki, Ronit Weizman, Dov Aizenberg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

The purpose of this study was to examine whether elderly chronic schizophrenia or schizoaffective disorder patients would clinically improve if switched to olanzapine from previous neuroleptic treatment. Twenty-one hospitalized patients, aged 60-88 yr, with a diagnosis of chronic schizophrenia or schizoaffective disorder who were being treated with typical neuroleptic medication were switched to olanzapine. The Positive and Negative Symptom Scale (PANSS), Geriatric Depression Scale (GDS) and Clinical Global Impression - Severity (CGI-S) Scale were completed while patients were on their previous medication regimen and again 6 months after the last patient had been started on olanzapine. The mean duration of treatment was 289 d (S.D. = 139). Three patients discontinued the medication. Mean end dose of olanzapine was 12.9 mg (S.D. = 5.7). Paired sample t tests were used to test change on PANSS Positive, Negative and Total scales, CGI, GDS and body weight. PANSS (Positive, p = 0.002; Negative, p = 0.003; General, p = 0.003; and Total, p = 0.000) and CGI (p = 0.000) but not the GDS (p = 0.67) demonstrated statistically significant improvement. There was no significant change in body weight (p=0.61). Elderly patients with aggravation of chronic schizophrenia showed improvement after being switched to olanzapine with no weight gain. Clinically meaningful change was observed in positive and negative psychotic symptomatology but not in depressive symptoms.

Original languageEnglish
Pages (from-to)165-169
Number of pages5
JournalInternational Journal of Neuropsychopharmacology
Volume7
Issue number2
DOIs
StatePublished - Jun 2004

Keywords

  • Elderly
  • Olanzapine
  • Psychosis
  • Switch

Fingerprint

Dive into the research topics of 'Switching elderly chronic psychotic patients to olanzapine'. Together they form a unique fingerprint.

Cite this